1[1]Mangelsdorf DJ,Thummel C,Beato M,et al. The nuclear receptor superfamily:The second decade[J]. Cell,1995, 83:835-839.
2[2]Laudet V. Evolution of the nuclear receptor superfamily:Early diversification from an ancestral orphan receptor[J]. J Mol Endocrinol,1997,19:207-226.
3[3]Cooke PS,Young P,Cunha GR. Androgen receptor expression in developing male reproductive organs[J]. Endocrinology,1991,128:2867-2873.
4[4]Donjacour AA,Cunha GR. Assessment of prostatic protein secretion in tissue recombinants made of urogenital sinus mesencheyme and urothelium from normal or androgeninsensitive mice[J]. Endocrinology,1993,132:2342.
5[5]Sherwwod ER,Fong CJ,Lee C,et al. Basic fibroblast growth factor:A potential mediator of stromal growth in the human prostate[J]. Endocrinology,1992,130:2953-2963.
6[6]Story M. Regulation of prostate growth by fibroblast growth factors[J]. World J Urol,1996,13:297-305.
7[7]Barraack ER. TGF beta in prostate cancer:A growth inhibitor that can enhance tumorigenicity[J]. Prostate,1997,31:61-70.
8[8]Kyprianou N,English HG,Isaacs JT. Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation[J]. Cancer Res,1990,50:3748-3753.
9[9]Boudon C,Rodier G,Lechevallier E,et al. Secretion of insulin-like growth factors and their binding proteins by human normal and hyperplastic prostatic cells in primary culture[J]. J Clin Endocrinol Metab,1996,81:612-617.
10[10]Kanety H,Madjar Y,Dagan Y,et al. Serum insulin-like growth factor-binding protein-2(IGFBP-2)is increased and IGFBP-3 is decreased in patients with prostate cancer:Correlation with serum prostate-specific antigen[J]. J Clin Endocrinol Metab,1993,77:229-233.
2Barnes DM,Dublin EA,Fisher C J,et al.Immnohistochemical detecion of P53 protein in mammry carcinoma:an important new independent indicator of prognosis[J].Hum Pathol,1993,24(5):469-476.
3Gleave ME,La Bianca SE,Goldenberg SL.Long-term neoadjuvant hormone therapy prior to radical prostatectomy:evaluation of risk for biochemical recurrence at 5-year follow-up[J].Urology,2000,56(2):289-294.
4See WA,Wirth MP,McLeod DG,et al.Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer:first analysis of the early prostate cancer program[J].UIrology,2002,168(2):429-435.
5Sarosdy MF,Schellhammer PF,Johnson R,et al.Does prolonged combined androgen blockade have survival benefits over short-term combined androgen blockade therapy[J] ? Urolology,2000,55(3):391-395.
